ALVR
vs
S&P 500
ALVR
S&P 500
Over the past 12 months, ALVR has underperformed S&P 500, delivering a return of +11% compared to the S&P 500's +14% growth.
Stocks Performance
ALVR vs S&P 500
Performance Gap
ALVR vs S&P 500
Performance By Year
ALVR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Allovir Inc
Glance View
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.
